

Oxford Biomedica plc

Questions and Answers

ANNUAL GENERAL MEETING

held at the offices of OXB

on 7 May 2026 at 3.00 p.m.

Oxford Biomedica plc

ANNUAL GENERAL MEETING

Questions and Answers

Any questions answered on the day or sent to us via email in advance of the meeting are outlined below.

Q. Broadly, when would you anticipate Durham reaching a standalone cashflow breakeven run-rate?

A. We do not split out financials or per site in this way. Guidance is always provided at the Group level.

Our focus across the business is on achieving sustainable profitability through continuing to grow our top line and focusing on margin expansion through increased scale and better capacity utilisation.

Q. Assuming a third GMP suite is brought online in Durham, at what point do you anticipate achieving high utilisation levels at the facility?

A. We can't provide a specific timeframe here but the Durham facility addresses our need for commercial capacity in the US, providing us with a larger US footprint to meet growing client demand.

The current Durham site has a c.121,000 sq ft. campus: two operational GMP drug substance suites, a dedicated fill-finish suite, a further GMP suite which is expansion-ready, as well as on-site QC labs and warehousing.